First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland
Belzutifan is a new HIF-α inhibitor mainly used in two different indications: von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and pancreatic neuroendocrine tumours, as well as sporadic advanced pre-treated renal cell carcinoma. Although efficacy has been demonstrated i...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/2/64 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850080744283570176 |
|---|---|
| author | Tobias Peres Stefanie Aeppli Stefanie Fischer Thomas Hundsberger Christian Rothermundt |
| author_facet | Tobias Peres Stefanie Aeppli Stefanie Fischer Thomas Hundsberger Christian Rothermundt |
| author_sort | Tobias Peres |
| collection | DOAJ |
| description | Belzutifan is a new HIF-α inhibitor mainly used in two different indications: von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and pancreatic neuroendocrine tumours, as well as sporadic advanced pre-treated renal cell carcinoma. Although efficacy has been demonstrated in phase II and III studies, belzutifan is still not approved in many countries. In addition, von Hippel–Lindau syndrome is a rare disease. Therefore, there is virtually no real-world experience data of belzutifan efficacy available. We aim to determine the real-world efficacy and tolerability of belzutifan in patients with von Hippel–Lindau syndrome-associated tumours and in patients with sporadic advanced tyrosine kinase- and immune checkpoint inhibitors pre-treated for renal cell carcinoma. A retrospective analysis of five patients treated with belzutifan between 2023 and 2024 at a Swiss cancer centre was conducted. In this case series, all patients consistently benefitted from belzutifan with response to treatment. This case series provides real-world evidence that belzutifan is an effective and well-tolerated treatment option for patients with von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and sporadic advanced pre-treated renal cell carcinoma. |
| format | Article |
| id | doaj-art-b4624d15da124b2bb4c860f8eabfe7f8 |
| institution | DOAJ |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-b4624d15da124b2bb4c860f8eabfe7f82025-08-20T02:44:53ZengMDPI AGCurrent Oncology1198-00521718-77292025-01-013226410.3390/curroncol32020064First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in SwitzerlandTobias Peres0Stefanie Aeppli1Stefanie Fischer2Thomas Hundsberger3Christian Rothermundt4Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen (KSSG), 9000 St. Gallen, SwitzerlandDepartment of Medical Oncology and Hematology, Cantonal Hospital St. Gallen (KSSG), 9000 St. Gallen, SwitzerlandDepartment of Medical Oncology and Hematology, Cantonal Hospital St. Gallen (KSSG), 9000 St. Gallen, SwitzerlandDepartment of Medical Oncology and Hematology, Cantonal Hospital St. Gallen (KSSG), 9000 St. Gallen, SwitzerlandDepartment of Medical Oncology and Cancer Centre, Cantonal Hospital Lucerne (LUKS), 6000 Lucerne, SwitzerlandBelzutifan is a new HIF-α inhibitor mainly used in two different indications: von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and pancreatic neuroendocrine tumours, as well as sporadic advanced pre-treated renal cell carcinoma. Although efficacy has been demonstrated in phase II and III studies, belzutifan is still not approved in many countries. In addition, von Hippel–Lindau syndrome is a rare disease. Therefore, there is virtually no real-world experience data of belzutifan efficacy available. We aim to determine the real-world efficacy and tolerability of belzutifan in patients with von Hippel–Lindau syndrome-associated tumours and in patients with sporadic advanced tyrosine kinase- and immune checkpoint inhibitors pre-treated for renal cell carcinoma. A retrospective analysis of five patients treated with belzutifan between 2023 and 2024 at a Swiss cancer centre was conducted. In this case series, all patients consistently benefitted from belzutifan with response to treatment. This case series provides real-world evidence that belzutifan is an effective and well-tolerated treatment option for patients with von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and sporadic advanced pre-treated renal cell carcinoma.https://www.mdpi.com/1718-7729/32/2/64belzutifanHIF-α inhibitorvon Hippel–Lindau syndromerenal cell carcinomahaemangioblastomascase series |
| spellingShingle | Tobias Peres Stefanie Aeppli Stefanie Fischer Thomas Hundsberger Christian Rothermundt First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland Current Oncology belzutifan HIF-α inhibitor von Hippel–Lindau syndrome renal cell carcinoma haemangioblastomas case series |
| title | First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland |
| title_full | First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland |
| title_fullStr | First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland |
| title_full_unstemmed | First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland |
| title_short | First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland |
| title_sort | first single centre experience with the novel hif α inhibitor belzutifan in switzerland |
| topic | belzutifan HIF-α inhibitor von Hippel–Lindau syndrome renal cell carcinoma haemangioblastomas case series |
| url | https://www.mdpi.com/1718-7729/32/2/64 |
| work_keys_str_mv | AT tobiasperes firstsinglecentreexperiencewiththenovelhifainhibitorbelzutifaninswitzerland AT stefanieaeppli firstsinglecentreexperiencewiththenovelhifainhibitorbelzutifaninswitzerland AT stefaniefischer firstsinglecentreexperiencewiththenovelhifainhibitorbelzutifaninswitzerland AT thomashundsberger firstsinglecentreexperiencewiththenovelhifainhibitorbelzutifaninswitzerland AT christianrothermundt firstsinglecentreexperiencewiththenovelhifainhibitorbelzutifaninswitzerland |